Somasundaram Jeevanandham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Somasundaram Jeevanandham has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
D Dhachinamoorthi
2 shared publications- Anasuya Patil
Department of Pharmaceutics II Block Rajajinagar KLE College of Pharmacy Bengaluru
1 shared publication B. Hema Kiranmayi
Aditya College of Pharmacy, Surampalem – 533437, Andhra Pradesh, India
1 shared publicationBoboxonova Muhayyoxon Mo'Minjonovna
Department of Folk Medicine and Pharmacology, Fergana Medical Institute of Public Health, Yangi Turon, Fergana – 150100, Uzbekistan
1 shared publicationDuraiswamy Dhachinamoorthi
QIS College of Pharmacy, Ongole
1 shared publicationGiridhar Kunamaneni
Northeastern University, 360 Huntington Ave, Boston, Massachusetts 02115, USA
1 shared publication
Latest Publications
- 10 April 2026
- Published by Dr. Yashwant Research Labs Pvt. Ltd. in International Journal of Drug Delivery Technology
Targeted Nose-to-Brain Delivery Using Functionalized Nanoparticles for Cognitive Restoration in Alzheimer's Disease
Alzheimer's disease (AD) represents the most prevalent and devastating form of age-related neurodegenerative disorder, characterized by progressive cognitive decline, memory impairment, and neuropsychiatric symptoms that arise from the accumulation of amyloid-beta (Aβ) plaques, neurofibrillary tau tangles, and chronic neuroinflammation. A major obstacle in the pharmacological management of AD is the inability of most therapeutic agents to cross the blood-brain barrier (BBB) in therapeutically meaningful concentrations following conventional systemic administration. The present investigation focuses on the design, fabrication, and comprehensive in vitro characterization of functionalized polymeric nanoparticles (NPs) loaded with Donepezil hydrochloride (DPZ), a first-line acetylcholinesterase inhibitor, intended for intranasal delivery as a novel cognitive restoration platform in Alzheimer's disease. Poly(lactic-co-glycolic acid) (PLGA) and chitosan were selected as the primary polymeric matrices and surface-functionalization agents, respectively, owing to their well-established biocompatibility, biodegradability, mucoadhesive properties, and ability to enhance cellular uptake. Eight distinct nanoparticle formulations (F1–F8) were systematically developed by varying PLGA concentration, chitosan coating levels, drug-to-polymer ratios, and the addition of stabilizers such as polyvinyl alcohol (PVA). The formulations were evaluated for particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency (EE%), drug loading (DL%), in vitro drug release behavior using Franz diffusion cells, mucoadhesive strength, and ex vivo nasal permeation. Optimized formulations demonstrated particle sizes in the range of 145–310 nm, positive zeta potentials (due to chitosan coating), encapsulation efficiencies exceeding 72%, and sustained biphasic drug release profiles extending over 24 hours, with enhanced mucoadhesive properties suitable for prolonged olfactory epithelium contact time. The results demonstrate that chitosan-coated PLGA nanoparticles represent an effective and tunable platform for nose-to-brain delivery of anti-Alzheimer drugs, with significant potential for advancing translational research in neurodegenerative disease therapy. Keywords: Alzheimer's disease; nose-to-brain delivery; PLGA nanoparticles; chitosan; intranasal drug delivery; bloodbrain barrier; donepezil.
- 10 April 2026
- Published by Dr. Yashwant Research Labs Pvt. Ltd. in International Journal of Drug Delivery Technology
Targeted Nose-to-Brain Delivery Using Functionalized Nanoparticles for Cognitive Restoration in Alzheimer's Disease
Alzheimer's disease (AD) represents the most prevalent and devastating form of age-related neurodegenerative disorder, characterized by progressive cognitive decline, memory impairment, and neuropsychiatric symptoms that arise from the accumulation of amyloid-beta (Aβ) plaques, neurofibrillary tau tangles, and chronic neuroinflammation. A major obstacle in the pharmacological management of AD is the inability of most therapeutic agents to cross the blood-brain barrier (BBB) in therapeutically meaningful concentrations following conventional systemic administration. The present investigation focuses on the design, fabrication, and comprehensive in vitro characterization of functionalized polymeric nanoparticles (NPs) loaded with Donepezil hydrochloride (DPZ), a first-line acetylcholinesterase inhibitor, intended for intranasal delivery as a novel cognitive restoration platform in Alzheimer's disease. Poly(lactic-co-glycolic acid) (PLGA) and chitosan were selected as the primary polymeric matrices and surface-functionalization agents, respectively, owing to their well-established biocompatibility, biodegradability, mucoadhesive properties, and ability to enhance cellular uptake. Eight distinct nanoparticle formulations (F1–F8) were systematically developed by varying PLGA concentration, chitosan coating levels, drug-to-polymer ratios, and the addition of stabilizers such as polyvinyl alcohol (PVA). The formulations were evaluated for particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency (EE%), drug loading (DL%), in vitro drug release behavior using Franz diffusion cells, mucoadhesive strength, and ex vivo nasal permeation. Optimized formulations demonstrated particle sizes in the range of 145–310 nm, positive zeta potentials (due to chitosan coating), encapsulation efficiencies exceeding 72%, and sustained biphasic drug release profiles extending over 24 hours, with enhanced mucoadhesive properties suitable for prolonged olfactory epithelium contact time. The results demonstrate that chitosan-coated PLGA nanoparticles represent an effective and tunable platform for nose-to-brain delivery of anti-Alzheimer drugs, with significant potential for advancing translational research in neurodegenerative disease therapy. Keywords: Alzheimer's disease; nose-to-brain delivery; PLGA nanoparticles; chitosan; intranasal drug delivery; bloodbrain barrier; donepezil.
- 1 September 2011
- Vol. ume 10 (Number 3) , 597-603
Drug Release Studies from Caesalpinia pulcherrima Seed Polysaccharide
- 1 September 2011
- Vol. ume 10 (Number 3) , 597-603
Drug Release Studies from Caesalpinia pulcherrima Seed Polysaccharide
- 1 January 2010
- Published by BRNSS Publication Hub in Asian Journal of Pharmaceutics
- Vol. 4 (2) , 135
Fabrication and evaluation of oral tablets using natural mucoadhesive agent from seeds of Caesalpinia pulcherrima (L.) SW
Oral mucoadhesive sustained drug delivery systems of salbutamol sulfate were formulated using an isolated natural agent from the seeds of Caesalpinia pulcherrima. The isolated material was evaluated for various parameters, such as, melting point, viscosity, pH, elemental analysis, swelling index, phytochemical constituents, and solubility studies. The mucoadhesive characters of the isolated substance were identified by a comparative study with hydroxyl propyl cellulose and sodium alginate, by various in vitro methods, such as, Shear stress measurement, Wilhelmy's method, Falling sphere method, and Detachment force measurement. Formulation and evaluation of mucoadhesive oral tablets of salbutamol sulfate (100 mg), using isolated natural materials in different proportions, and in vitro release studies, were carried out for three different formulations according to the U.S.P apparatus two (paddle method). Each 100 mg tablet was taken in 900 ml of acid buffer 1.2 and maintained at 37˚C. After two hours the filtrate was collected and replaced in buffer 7.4. In vitro releases of three different formulations for nine hours were studied, which showed the sustained action of drug release with increasing the concentration of the isolated natural mucoadhesive agent in the formulations.
- 1 January 2010
- Published by BRNSS Publication Hub in Asian Journal of Pharmaceutics
- Vol. 4 (2) , 135
Fabrication and evaluation of oral tablets using natural mucoadhesive agent from seeds of Caesalpinia pulcherrima (L.) SW
Oral mucoadhesive sustained drug delivery systems of salbutamol sulfate were formulated using an isolated natural agent from the seeds of Caesalpinia pulcherrima. The isolated material was evaluated for various parameters, such as, melting point, viscosity, pH, elemental analysis, swelling index, phytochemical constituents, and solubility studies. The mucoadhesive characters of the isolated substance were identified by a comparative study with hydroxyl propyl cellulose and sodium alginate, by various in vitro methods, such as, Shear stress measurement, Wilhelmy's method, Falling sphere method, and Detachment force measurement. Formulation and evaluation of mucoadhesive oral tablets of salbutamol sulfate (100 mg), using isolated natural materials in different proportions, and in vitro release studies, were carried out for three different formulations according to the U.S.P apparatus two (paddle method). Each 100 mg tablet was taken in 900 ml of acid buffer 1.2 and maintained at 37˚C. After two hours the filtrate was collected and replaced in buffer 7.4. In vitro releases of three different formulations for nine hours were studied, which showed the sustained action of drug release with increasing the concentration of the isolated natural mucoadhesive agent in the formulations.
- 1 January 2010
- Published by BRNSS Publication Hub in Asian Journal of Pharmaceutics
- Vol. 4 (1) , 48
Formulation and evaluation of naproxen sodium orodispersible tablets - A sublimation technique
- 1 January 2010
- Published by BRNSS Publication Hub in Asian Journal of Pharmaceutics
- Vol. 4 (1) , 48
Formulation and evaluation of naproxen sodium orodispersible tablets - A sublimation technique